{"id":"W1962960638","doi":"10.3109/10428194.2015.1091927","title":"A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191","year":2015,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":38,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre; University of Alberta; Juravinski Cancer Centre; Saint John Regional Hospital; Dalhousie University; University of New Brunswick; Queen's University","funders":"","keywords":"Multiple myeloma; Medicine; Refractory (planetary science); Internal medicine; Oncology; Clinical trial; Kinase; Malignancy; Aurora A kinase; Aurora kinase; Cancer; Biology; Cell cycle","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001511007,0.0006022689,0.001331045,0.0002115573,0.0006122412,0.0009415505,0.0008039855,0.0054483,0.003003335],"category_scores_gemma":[0.001512061,0.00021761,0.0007628654,0.0003391863,0.0005452933,0.0007195526,0.0002921319,0.005442405,0.001267832],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001202438,"about_ca_system_score_gemma":0.0007876389,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001060848,"about_ca_topic_score_gemma":0.003897935,"domain_scores_codex":[0.9995416,0.0001910696,0.00003455851,0.00006285959,0.00008957234,0.00008031219],"domain_scores_gemma":[0.9993303,0.00028617,0.00006132288,0.00003326987,0.00006135757,0.0002276182],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.06527036,0.004864653,0.01080165,0.0008375316,0.0007164986,0.01043517,0.0002416339,0.001819219,0.01564933,0.002839049,0.5989438,0.2875811],"study_design_scores_gemma":[0.3410497,0.07789452,0.0520025,0.0007175985,0.001464002,0.01407109,0.0004793865,0.01083008,0.01275618,0.01314984,0.4753129,0.0002720997],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"empirical","genre_scores_codex":[0.3238225,0.05141358,0.002709871,0.5483527,0.01962531,0.002520472,0.005183815,0.0005597164,0.04581193],"genre_scores_gemma":[0.5972002,0.01858891,0.004448188,0.3158552,0.01317103,0.00175899,0.003548057,0.0001296799,0.04529979],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.0054483,"threshold_uncertainty_score":0.01004714,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03363137153877019,"score_gpt":0.313103503236891,"score_spread":0.2794721316981208,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}